Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.

ABSTRACT:

Purpose

Although anti-CD25 recombinant immunotoxin LMB-2 is effective against CD25(+) hairy cell leukemia, activity against more aggressive diseases such as adult T-cell leukemia (ATL) is limited by rapid disease progression between treatment cycles. Our goal was to determine in vivo whether rapid growth of CD25(+) tumor is associated with high levels of tumor interstitial soluble CD25 (sCD25) and whether chemotherapy can reduce tumor sCD25 and synergize with LMB-2.

Experimental design

Tumor xenografts expressing human CD25 were grown in mice, which were then treated with LMB-2 and chemotherapy either alone or in combination, and sCD25 level and antitumor activity were measured.

Results

CD25(+) human xenografts growing rapidly in nude mice had intratumoral sCD25 at le

SUBMITTER: Singh R 

PROVIDER: S-EPMC3251712 | biostudies-literature | 2012 Jan

REPOSITORIES: biostudies-literature